Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

GlobeNewswire August 16, 2021

Travere Therapeutics Reports Second Quarter 2021 Financial Results

GlobeNewswire July 29, 2021

Travere Therapeutics to Report Second Quarter 2021 Financial Results

GlobeNewswire July 22, 2021

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

GlobeNewswire June 7, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

Newsfile June 5, 2021

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

GlobeNewswire June 4, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

GlobeNewswire June 2, 2021

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

GlobeNewswire June 2, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

PR Newswire June 1, 2021

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 27, 2021

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Travere Therapeutics, Inc. (TVTX) Investigation

ACCESSWIRE IA May 26, 2021

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

GlobeNewswire May 25, 2021

Travere Therapeutics Reports First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

GlobeNewswire April 27, 2021

Travere Therapeutics to Report First Quarter 2021 Financial Results

GlobeNewswire April 26, 2021

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 1, 2021

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

GlobeNewswire February 25, 2021

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 22, 2021

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

GlobeNewswire February 18, 2021